BRANCHAMIN 4% Drug Patent Profile
Which patents cover Branchamin 4%, and what generic alternatives are available?
Branchamin 4% is a drug marketed by Baxter Hlthcare and is included in two NDAs.
The generic ingredient in BRANCHAMIN 4% is amino acids. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the amino acids profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Branchamin 4%
A generic version of BRANCHAMIN 4% was approved as amino acids by B BRAUN on April 13th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BRANCHAMIN 4%?
- What are the global sales for BRANCHAMIN 4%?
- What is Average Wholesale Price for BRANCHAMIN 4%?
Summary for BRANCHAMIN 4%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| DailyMed Link: | BRANCHAMIN 4% at DailyMed |
US Patents and Regulatory Information for BRANCHAMIN 4%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | BRANCHAMIN 4% | amino acids | INJECTABLE;INJECTION | 018678-001 | Sep 28, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare | BRANCHAMIN 4% IN PLASTIC CONTAINER | amino acids | INJECTABLE;INJECTION | 018684-001 | Sep 28, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BRANCHAMIN 4%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | BRANCHAMIN 4% | amino acids | INJECTABLE;INJECTION | 018678-001 | Sep 28, 1984 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BRANCHAMIN 4%
See the table below for patents covering BRANCHAMIN 4% around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 7456581 | ⤷ Start Trial | |
| European Patent Office | 0057209 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 8200411 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BRANCHAMIN 4%
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0925294 | SPC/GB07/047 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619 |
| 0925294 | SZ 56/2007 | Austria | ⤷ Start Trial | PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES |
| 0812190 | SPC/GB05/042 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch